KLHDC8A Regulates M1/M2 Macrophage Polarization Through the PD-1/STAT3 Pathway to Promote Papillary Thyroid Cancer Development.

[BACKGROUND] Papillary thyroid cancer (PTC) is one of the most frequent endocrine malignancies. Kelch domain containing 8A (KLHDC8A) is reported as an epigenetically driven oncogene, but the role of KLHDC8A in PTC is still unclear. This study aimed to explore the function of KLHDC8A in PTC progression.

[METHODS] KLHDC8A expression was analyzed by the Gene Expression Profiling Interactive Analysis (GEPIA) website, quantitative real-time PCR (qRT-PCR), and western blot. The viability of PTC cells (TPC-1 and BCPAP) was assessed by cell counting kit-8 (CCK-8) kit. A transwell assay was carried out to evaluate the invasion and migration of PTC cells. Macrophage polarization-associated markers were determined by qRT-PCR and western blot. Mice tumor xenograft models were established to analyze the role of KLHDC8A . Pathway-related proteins (programmed cell death protein 1 (PD-1) and signal transducer and activator of transcription 3 (STAT3)) were determined by western blot.

[RESULTS] GEPIA demonstrated that KLHDC8A was highly expressed in PTC ( < 0.05). Knockdown of KLHDC8A hindered cell viability, invasion, and migration of PTC cells ( < 0.0001). Additionally, KLHDC8A knockdown inhibited M2 polarization while promoting M1 polarization ( < 0.0001). Meanwhile, KLHDC8A silencing inhibited tumor growth in mice xenografted models ( < 0.0001). Moreover, the PD-1/STAT3 pathway was suppressed by KLHDC8A silencing ( < 0.01), and the STAT3 activator (colivelin) attenuated the inhibitory effects of KLHDC8A silencing on PTC progression ( < 0.01).

[CONCLUSIONS] Through and experiments, KLHDC8A silencing could restrain PTC cell viability, migration, and invasion, inhibit tumor growth, and promote M1 polarization via the PD-1/STAT3 axis, providing a new therapeutic idea for PTC clinical treatment.